| Literature DB >> 33643293 |
Lisa Kornstädt1, Sandra Pierre1, Andreas Weigert2, Stefanie Ebersberger3, Tim J Schäufele1, Anja Kolbinger1, Tobias Schmid2, Jennifer Cohnen1, Dominique Thomas1, Nerea Ferreirós1, Bernhard Brüne2,4, Ingo Ebersberger5,6,7, Klaus Scholich1,4,8.
Abstract
Next to their role in IgE-mediated allergic diseases and in promoting inflammation, mast cells also have antiinflammatory functions. They release pro- as well as antiinflammatory mediators, depending on the biological setting. Here we aimed to better understand the role of mast cells during the resolution phase of a local inflammation induced with the Toll-like receptor (TLR)-2 agonist zymosan. Multiple sequential immunohistology combined with a statistical neighborhood analysis showed that mast cells are located in a predominantly antiinflammatory microenvironment during resolution of inflammation and that mast cell-deficiency causes decreased efferocytosis in the resolution phase. Accordingly, FACS analysis showed decreased phagocytosis of zymosan and neutrophils by macrophages in mast cell-deficient mice. mRNA sequencing using zymosan-induced bone marrow-derived mast cells (BMMC) revealed a strong type I interferon (IFN) response, which is known to enhance phagocytosis by macrophages. Both, zymosan and lipopolysaccharides (LPS) induced IFN-β synthesis in BMMCs in similar amounts as in bone marrow derived macrophages. IFN-β was expressed by mast cells in paws from naïve mice and during zymosan-induced inflammation. As described for macrophages the release of type I IFNs from mast cells depended on TLR internalization and endosome acidification. In conclusion, mast cells are able to produce several mediators including IFN-β, which are alone or in combination with each other able to regulate the phagocytotic activity of macrophages during resolution of inflammation.Entities:
Keywords: IFN-β; inflammation; mast cells; phagocytosis; resolution; toll-like receptor
Mesh:
Substances:
Year: 2021 PMID: 33643293 PMCID: PMC7907501 DOI: 10.3389/fimmu.2020.607048
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561